

<b>Product Name</b>	: BMS-986165
<b>Synonyms</b>	: —
<b>Cat No.</b>	: M21721
<b>CAS Number</b>	: 1609392-27-9
<b>Molecular Formula</b>	: C <sub>20</sub> H <sub>19</sub> D <sub>3</sub> N <sub>8</sub> O <sub>3</sub>
<b>Formula Weight</b>	: 425.46
<b>Chemical Name</b>	: —
<b>Description</b>	: BMS-986165 is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism. BMS-986165 maintains excellent potency in human and mouse whole blood (IC <sub>50</sub> s=13 and 100 nM, respectively) and shows no significant hERG inhibition in the flux assay (IC <sub>50</sub> >80 μM).
<b>Pathway</b>	: Angiogenesis
<b>Target</b>	: JAK
<b>Receptor</b>	: —
<b>Solubility</b>	: DMSO : 37.5 mg/mL (88.14 mM; Need ultrasonic)
<b>SMILES</b>	: <chem>O=C(C1=NN=C(NC(C2CC2)=O)C=C1NC3=CC=CC(C4=NN(C)C=N4)=C3OC)NC([2H])([2H])([2H])</chem>
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

1. Wroblewski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019 Jul 18. 2. Catlett I, et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Annals of the Rheumatic Diseases 2017; 76:859.